EIGER BIOPHARMACEUTICALS, INC.

Analyst Reco. Eiger BioPharmaceuticals, Inc.

Equities

EIGR

US28249U2042

Market Closed - OTC Markets Other stock markets 01:29:47 27/04/2024 am IST			5-day change	1st Jan Change
2.67 ^USD	-12.17%		+11.72%	-60.36%

10/04	Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from NASDAQ Composite Index	CI
08/04	Eiger BioPharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

News Highlights : Top Company News of the Day - Monday at 11 PM ET	02/04	DJ
News Highlights : Top Company News of the Day - Monday at 7 PM ET	02/04	DJ
Citigroup Adjusts Eiger BioPharmaceuticals Price Target to $3 From $4, Maintains Buy Rating	29/23/29	MT
Baird Adjusts Price Target on Eiger BioPharmaceuticals to $5 From $3, Maintains Outperform Rating	30/23/30	MT
BTIG Adjusts Eiger BioPharmaceuticals' Price Target to $48 from $57, Maintains Buy Rating	07/22/07	MT
EIGER BIOPHARMACEUTICALS : Wedbush Suspended Coverage on Eiger BioPharmaceuticals	11/21/11	MT
EIGER BIOPHARMACEUTICALS : Citigroup Adjusts Price Target on Eiger BioPharmaceuticals to $26 From $23, Maintains Buy Rating	11/21/11	MT
EIGER BIOPHARMACEUTICALS : Wedbush Lifts Price Target for Eiger BioPharmaceuticals to $23 From $22, Maintains Outperform Rating	10/21/10	MT
EIGER BIOPHARMACEUTICALS : Wedbush Adjusts Price Target for Eiger BioPharmaceuticals to $22 From $31, Maintains Outperform Rating	26/20/26	MT
EIGER BIOPHARMACEUTICALS : Wedbush Adjusts Price Target on Eiger BioPharmaceuticals to $31 From $32, Keeps Outperform Rating	06/20/06	MT
Eiger BioPharmaceuticals, Inc. Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to 'All-Oral' Lonafarnib-Ritonavir Regimen in Low Viral Load Hdv-Infected Patients At the International Liver Congress 2018	17/18/17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer